# Pizarra — PT-pseudo_dd011d696387 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dd011d696387
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 75-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.372 ng/mL²
  - PSA velocity: 0.55 ng/mL/yr
  - Prior PSA: 14.0 ng/mL
  - Prostate volume: 26.91 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8577571 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: atorvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 27 mL. csPCa 0.86.

Vitals: weight 92 kg, height 179 cm, BMI 28.7, BP 101/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2002).

Chief complaint: Clinical attention sought for reassessment of a previously confirmed prostate malignancy alongside recent fluctuations in prostate-specific antigen levels.

History: Clinical review initiated to reassess a previously established prostate cancer diagnosis. At 75 years of age, he works as an active dairy farmer and resides independently as a widower, relying on his adult daughter as his main point of contact. Body mass indexes 28.7 at a weight of 92 kg. Tobacco use ceased in 2002, accounting for a cumulative 13 pack-year exposure. Chronic coronary artery disease remains controlled via atorvastatin, while tamsulosin addresses benign prostatic hyperplasia; lower urinary tract symptoms are negligible, scoring just 2 on the IPSS scale. Daily life centers around agricultural work, with otherwise limited physical activity. Alcohol intake stays around three units weekly. Public transit limitations dictate a preference for morning visits. A decades-old meniscal injury occasionally flares during wet conditions, and he maintains routine cardiology appointments solely for blood pressure tracking. Unexplained weight reduction, skeletal discomfort, and blood in the urine are firmly denied, as he prioritizes continuing his agricultural schedule. December 2024 bloodwork revealed a prostate-specific antigen level of 10.0 ng/mL (free fraction 16%), complemented by unremarkable renal panels and complete blood counts. No medication sensitivities exist.

Physical examination: Digital rectal examination proves normal; the prostate presents as symmetrically enlarged with a smooth, firm consistency and absent nodules or asymmetry. Hemodynamic parameters show a blood pressure of 101/75 mmHg and a pulse of 73 beats per minute. Systemic assessment identifies a well-nourished individual exhibiting no signs of acute distress; pulmonary fields are clear and cardiac rhythm remains regular.

Patient info: active dairy farmer; Widowed; Lives alone; adult daughter is primary contact.
Next of kin: None recorded — patient declines to nominate.

Lifestyle: alcohol 3 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 2/35 (mild LUTS).


Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.59 +/- 0.20   (95% CI 0.20-0.92)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.4 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=10.0, age=75.0, psad=0.372, dre_ord=0.0, vol=26.91, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS=5, PSA=10.0, prior biopsy positive, csPCa probability=0.8577571) and could not weigh the context provided by the retrieved documents, such as the specific MRI findings, PSA trajectory, or laboratory panel details.
Specifically, it failed to incorporate the specific PSA velocity (0.55 ng/mL/yr) or the PSA density (0.372 ng/mL²), which are critical for risk stratification, and the context of the prior positive biopsy status relative to the current PI-RADS 5 finding.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a wide uncertainty interval (0.59 +/- 0.20), indicating the classifier is genuinely unable to distinguish between the two outcomes based on the limited input. The suggestion could be wrong because the prior did not account for the guideline criterion that the decision hinges on the retrieved documents, specifically whether the prior grade is documented or if the lesion has changed on MRI. Furthermore, a high csPCa probability (0.8577571) combined with a normal DRE might be misinterpreted by a simple classifier as a strong indication for immediate intervention, ignoring the protocol's requirement to check the retrieved data.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel
The radiology report is crucial because the guideline states that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous, which is a factor the prior ignored. The PSA history is needed to assess the trajectory, which is a factor the prior did not weigh.

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_dd011d696387", "radiology_report": "UMCG Radiology | 08 Jan 2025 | Multiparametric MRI Prostate\nClinical Context: Assessment of previously identified malignancy. Recent serum prostate-specific antigen stands at 10.0 ng/mL (velocity 0.55 ng/mL/yr); baseline imaging carried a PI-RADS 5 designation.\nFINDINGS:\nGlandular dimensions register 26.91 mL. T2-weighted sequences disclose a discrete hypointense focus within the left peripheral zone at the base/mid-gland level, spanning roughly 14 mm. High b-value diffusion-weighted imaging exhibits pronounced restriction with matching low apparent diffusion coefficient values. Dynamic contrast enhancement demonstrates early, localized uptake compared to adjacent tissue. Capsular integrity remains intact; seminal vesicles are clear. Pelvic nodal basins appear normal. Skeletal structures lack suspicious marrow signal.\nIMPRESSION:\nPI-RADS 5 lesion in the left peripheral zone measuring approximately 14 mm. Prostate volume 26.91 mL yielding a PSA density of 0.372 ng/mL/mL. csPCa predicted probability 0.8577571."}
get_psa_trend
{"case_id": "PT-pseudo_dd011d696387", "psa_trend": [{"date": "Nov 2023", "val": 2.9}, {"date": "Mar 2024", "val": 1.2}, {"date": "Jun 2024", "val": 4.6}, {"date": "Sep 2024", "val": 8.7}, {"date": "Jan 2025", "val": 10.0}]}
get_previous_notes
{"case_id": "PT-pseudo_dd011d696387", "previous_notes": [{"date": "16 May 2024", "author": "Dr. M. Jansen (GP)", "text": "Annual wellness visit. Occasional nighttime voiding reported; otherwise asymptomatic. Initial prostate-specific antigen measurement measured 6.2 ng/mL. Follow-up testing scheduled for six months later to monitor the sustained elevation."}, {"date": "21 Jul 2023", "author": "Dr. M. Jansen (GP)", "text": "March 2024 follow-up shows PSA holding at 7.5 ng/mL. Mild daytime frequency noted without notable obstruction. Urology consultation arranged to investigate the ongoing marker elevation alongside earlier positive biopsy results."}]}
get_lab_results
{"case_id": "PT-pseudo_dd011d696387", "laboratory_results": [{"name": "PSA", "val": "10.0 ng/mL", "date": "16 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.61 ng/mL", "date": "16 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "16 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.3 g/dL", "date": "16 Dec 2024", "flag": ""}, {"name": "WBC", "val": "7.0 x10^9/L", "date": "16 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "221 x10^9/L", "date": "16 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "107 umol/L", "date": "16 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "16 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "12.7 nmol/L", "date": "16 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "73 U/L", "date": "16 Dec 2024", "flag": ""}, {"name": "LDH", "val": "199 U/L", "date": "16 Dec 2024", "flag": "H"}]}

NOT RETRIEVED
The pathology report was not retrieved because the prompt stated it was not available for this task.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion measuring approximately 14 mm in the left peripheral zone.
- PSA trend: Rising trajectory from 2.9 ng/mL (Nov 2023) to 10.0 ng/mL (Jan 2025), with a velocity of 0.55 ng/mL/yr.
- Previous notes: Urology consultation arranged to investigate ongoing marker elevation alongside earlier positive biopsy results.

AGAINST sampling this patient now:
- MRI report: Lesion is described as a discrete focus, and the context implies this is a re-evaluation of a known finding.
- Previous notes: No explicit mention of a surveillance protocol or a specific re-biopsy due date.

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the high-risk MRI finding (PI-RADS 5) and the rising PSA velocity, which contradicts the guideline criterion that the decision must be based on retrieved documents.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: uncertain)

The guideline criterion is undetermined because the retrieved documents do not explicitly state whether the prior grade is documented or if the lesion has changed on MRI. Since there is no documented prior grade, sampling is indicated to determine the current pathological status, despite the known prior diagnosis. The rising PSA velocity of 0.55 ng/mL/yr and the PI-RADS 5 finding support proceeding with biopsy to guide definitive management.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
